Onco3R Therapeutics develops precision small and large molecule drugs for autoimmune diseases and oncology. Their proprietary translational modeling platform and AI-driven design create best-in-class therapeutics with optimal target coverage, high selectivity, and reduced resistance.
Funding
Funding not disclosed
Founders
Product
Problem
Many approved therapies for autoimmune diseases and oncology indications exhibit suboptimal target coverage, lead to dose-limiting toxicities due to off-target inhibition, or are susceptible to treatment resistance. This results in a significant proportion of patients who either do not respond to treatment or experience adverse events, limiting therapeutic benefit and patient convenience.
Solution
Onco3R Therapeutics develops precision medicines designed to address these limitations in immunology and oncology. The company employs a patient-centric strategy focused on clinically validated targets, utilizing a proprietary translational modeling framework that integrates clinical data with _in vitro_ and _in vivo_ insights. This approach allows for the identification and mitigation of efficacy and safety gaps inherent in first-generation therapies. By leveraging advanced computational tools, structure-based drug design, and AI-augmented predictions, Onco3R aims to create best-in-class small and large molecule drugs with optimal target coverage, high selectivity, and minimal resistance. Early integration of pharmacokinetic and safety assessments is employed to de-risk development and accelerate the path to proof-of-concept.
Target Audience
The primary target audience includes pharmaceutical companies seeking to license or co-develop novel therapeutics, as well as clinical researchers and healthcare providers focused on advanced treatments for autoimmune diseases and oncology.
Features
- Development of both small molecule and large molecule (antibody-based) therapeutics.
- Focus on clinically validated targets with identified unmet needs in autoimmune diseases and oncology.
- Proprietary translational modeling platform integrating clinical, _in vitro_, and _in vivo_ data to guide drug design.
- Utilization of AI-driven predictions and structure-based design for optimizing drug potency and selectivity.
- Early integration of pharmacokinetic and safety profiling to mitigate late-stage attrition.
- Pipeline includes a Salt Inducible Kinase (SIK) inhibitor (O3R-5671) for immunology indications, targeting SIK3 to modulate inflammatory pathways.
- Precision oncology portfolio targeting specific genetic drivers, including selective FGFR3 inhibitors for bladder cancer, SMARCA2 inhibitors for SMARCA4-deficient NSCLC, and p53 Y220C reactivators.
- Design principles emphasize optimal target/pathway coverage, high selectivity to minimize off-target effects, and strategies to prevent treatment resistance.